Rhabdomyosarcoma

Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 1 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Alliance Pharmaceuticals
1 program
1
DasatinibPhase 2Small Molecule1 trial
Active Trials
NCT00464620Completed366Est. May 2017
One Biosciences
One BiosciencesFrance - Paris
1 program
1
VinorelbinePhase 11 trial
Active Trials
NCT04299113Active Not RecruitingEst. May 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Alliance PharmaceuticalsDasatinib
One BiosciencesVinorelbine

Clinical Trials (2)

Total enrollment: 366 patients across 2 trials

Trial of Dasatinib in Advanced Sarcomas

Start: May 2007Est. completion: May 2017366 patients
Phase 2Completed

Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma

Start: May 2020Est. completion: May 2027
Phase 1Active Not Recruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space